SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

2/14/22 3:24:07 PM ET

$ABCL

Pharmaceuticals and Biotechnology

Health Care

Get the next $ABCL alert in real time by email

SC 13G/A 1 tm226145d3_sc13ga.htm SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13G

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. 1) *

AbCellera Biologics Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

00288U106

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)
¨	Rule 13d-1(c)
x	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

Page 1 of 17 Pages

Exhibit Index Contained on Page 16

CUSIP NO. 00288U106

13G

Page 2 of 17

1	NAME OF REPORTING PERSON DCVC Bio, L.P. (“DCVC Bio”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 7,305,761 shares, except that DCVC Bio GP, LLC (“DCVC Bio GP”), the general partner of DCVC Bio, may be deemed to have sole voting power with respect to such shares, JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, and Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, and Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 7,305,761 shares, except that DCVC Bio GP, the general partner of DCVC Bio, may be deemed to have sole dispositive power with respect to such shares, JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, and Stead and Hamer, the managing members of JNK, and Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	7,305,761
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES*	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	2.6%
12	TYPE OF REPORTING PERSON*	PN

CUSIP NO. 00288U106

13G

Page 3 of 17

1	NAME OF REPORTING PERSON DCVC Bio GP, LLC (“DCVC Bio GP”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”), for whom DCVC Bio GP serves as general partner, except that JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, and Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, and Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 7,305,761 shares, all of which are held by DCVC Bio, for whom DCVC Bio GP serves as general partner, except that JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, and Stead and Hamer, the managing members of JNK, and Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	7,305,761
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	2.6%
12	TYPE OF REPORTING PERSON*	OO

CUSIP NO. 00288U106

13G

Page 4 of 17

1	NAME OF REPORTING PERSON JNK Capital Management, LLC (“JNK”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0 shares.
	6	SHARED VOTING POWER 7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). JNK serves as a managing member of DCVC Bio GP, LLC (“DCVC Bio GP”), the general partner of DCVC Bio, and may be deemed to have shared voting power with respect to such shares. Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, may be deemed to have shared voting power with respect to such shares.
	7	SOLE DISPOSITIVE POWER 0 shares.
	8	SHARED DISPOSITIVE POWER 7,305,761 shares, all of which are held by DCVC Bio. JNK serves as a managing member of DCVC Bio GP, the general partner of DCVC Bio, and may be deemed to have shared dispositive power with respect to such shares. Stead and Hamer, the managing members of JNK, may be deemed to have shared dispositive power with respect to such shares.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	7,305,761
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	2.6%
12	TYPE OF REPORTING PERSON*	OO

CUSIP NO. 00288U106

13G

Page 5 of 17

1	NAME OF REPORTING PERSON ZNM Capital Management, LLC (“ZNM”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0 shares.
	6	SHARED VOTING POWER 7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). ZNM serves as a managing member of DCVC Bio GP (“DCVC Bio GP”), the general partner of DCVC Bio, and may be deemed to have shared voting power with respect to such shares. Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
	7	SOLE DISPOSITIVE POWER 0 shares.
	8	SHARED DISPOSITIVE POWER 7,305,761 shares, all of which are held by DCVC Bio. ZNM serves as a managing member of DCVC Bio GP, the general partner of DCVC Bio, and may be deemed to have shared dispositive power with respect to such shares. Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	7,305,761
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	2.6%
12	TYPE OF REPORTING PERSON*	OO

CUSIP NO. 00288U106

13G

Page 6 of 17

1	NAME OF REPORTING PERSON Zachary Bogue (“Bogue”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0 shares
	6	SHARED VOTING POWER 7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Bogue, as a managing member of ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
	7	SOLE DISPOSITIVE POWER 0 shares
	8	SHARED DISPOSITIVE POWER 7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Bogue, as a managing member of ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	7,305,761
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	2.6%
12	TYPE OF REPORTING PERSON*	IN

CUSIP NO. 00288U106

13G

Page 7 of 17

1	NAME OF REPORTING PERSON Matthew Ocko (“Ocko”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0 shares
	6	SHARED VOTING POWER 7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Ocko, as a managing member of ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
	7	SOLE DISPOSITIVE POWER 0 shares
	8	SHARED DISPOSITIVE POWER 7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Ocko, as a managing member of ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	7,305,761
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	2.6%
12	TYPE OF REPORTING PERSON*	IN

CUSIP NO. 00288U106

13G

Page 8 of 17

1	NAME OF REPORTING PERSON Kiersten Stead (“Stead”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0 shares
	6	SHARED VOTING POWER 7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Stead, as a managing member of JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
	7	SOLE DISPOSITIVE POWER 0 shares
	8	SHARED DISPOSITIVE POWER 7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Stead, as a managing member of JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	7,305,761
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	2.6%
12	TYPE OF REPORTING PERSON*	IN

CUSIP NO. 00288U106

13G

Page 9 of 17

1	NAME OF REPORTING PERSON John Hamer (“Hamer”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0 shares
	6	SHARED VOTING POWER 7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Hamer, as a managing member of JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
	7	SOLE DISPOSITIVE POWER 0 shares
	8	SHARED DISPOSITIVE POWER 7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Hamer, as a managing member of JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	7,305,761
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	2.6%
12	TYPE OF REPORTING PERSON*	IN

CUSIP NO. 00288U106

13G

Page 10 of 17

ITEM 1(A).

NAME OF ISSUER

AbCellera Biologics Inc.

ITEM 1(B).

ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

2215 Yukon Street

Vancouver, BC V5Y 0A1

ITEM 2(A).

NAME OF PERSONS FILING

This Statement is filed by DCVC Bio, L.P., a Delaware limited partnership (“DCVC Bio”), DCVC Bio GP, LLC, a Delaware limited liability company (“DCVC Bio GP”), JNK Capital Management, LLC, a Delaware limited liability company (“JNK”), ZNM Capital Management, LLC, a Delaware limited liability company (“ZNM”), Zachary Bogue (“Bogue”), Matthew Ocko (“Ocko”), John Hamer (“Hamer”) and Kiersten Stead (“Stead”). The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

DCVC Bio GP is the general partner of DCVC Bio, and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. ZNM is a managing member of DCVC Bio GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. JNK is a managing member of DCVC Bio GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. Bogue and Ocko are managing members of ZNM and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. Hamer and Stead are managing members of JNK and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio.

ITEM 2(B).

ADDRESS OF PRINCIPAL OFFICE

The address for each of the Reporting Persons is:

270 University Avenue
Palo Alto, CA 94301

ITEM 2(C).

CITIZENSHIP

DCVC Bio is a Delaware limited partnership. DCVC Bio GP, JNK and ZNM are Delaware limited liability companies. Bogue, Ocko, Hamer and Stead are United States citizens.

ITEM 2(D) AND (E). TITLE OF CLASS OF SECURITIES AND CUSIP NUMBER

Common Shares, no par value per share
CUSIP # 00288U106

ITEM 3.

Not Applicable.

CUSIP NO. 00288U106

13G

Page 11 of 17

ITEM 4.

OWNERSHIP

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned:

See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class:

See Row 11 of cover page for each Reporting Person.

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote:

See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each Reporting Person.

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

ITEM 6.

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Under certain circumstances set forth in the limited partnership agreement of DCVC Bio, and the limited liability company agreements of DCVC Bio GP, JNK Capital Management, LLC and ZNM Capital Management, LLC, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a partner or member, as the case may be.

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

Not applicable.

CUSIP NO. 00288U106

13G

Page 12 of 17

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not applicable.

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP

Not applicable.

ITEM 10.

CERTIFICATION

Not applicable.

CUSIP NO. 00288U106

13G

Page 13 of 17

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2021

		DCVC Bio, L.P.

		By: DCVC Bio GP, LLC, its General Partner

		By: JNK Capital Management, LLC, its Managing Member

	By:	/s/ John Hamer
	Name:	John Hamer
	Title:	Managing Member

	By:	/s/ Kiersten Stead
	Name:	Kiersten Stead
	Title:	Managing Member

		By: ZNM Capital Management, LLC, its Managing Member

	By:	/s/ Matthew Ocko
	Name:	Matthew Ocko
	Title:	Managing Member

	By:	/s/ Zachary Bogue
	Name:	Zachary Bogue
	Title:	Managing Member

		DCVC Bio GP, LLC

		By: JNK Capital Management, LLC, its Managing Member

	By:	/s/ John Hamer
	Name:	John Hamer
	Title:	Managing Member

	By:	/s/ Kiersten Stead
	Name:	Kiersten Stead
	Title:	Managing Member

		By: ZNM Capital Management, LLC, its Managing Member

	By:	/s/ Matthew Ocko
	Name:	Matthew Ocko
	Title:	Managing Member

CUSIP NO. 00288U106

13G

Page 14 of 17

	By:	/s/ Zachary Bogue
	Name:	Zachary Bogue
	Title:	Managing Member

		JNK Capital Management, LLC

	By:	/s/ John Hamer
	Name:	John Hamer
	Title:	Managing Member

	By:	/s/ Kiersten Stead
	Name:	Kiersten Stead
	Title:	Managing Member

		ZNM Capital Management, LLC

	By:	/s/ Matthew Ocko
	Name:	Matthew Ocko
	Title:	Managing Member

	By:	/s/ Zachary Bogue
	Name:	Zachary Bogue
	Title:	Managing Member

		John Hamer

	By:	/s/ John Hamer
	Name:	John Hamer

		Kiersten Stead

	By:	/s/ Kiersten Stead
	Name:	Kiersten Stead

		Matthew Ocko

	By:	/s/ Matthew Ocko
	Name:	Matthew Ocko

		Zachary Bogue

	By:	/s/ Zachary Bogue
	Name:	Zachary Bogue

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

CUSIP NO. 00288U106

13G

Page 15 of 17

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

CUSIP NO. 00288U106

13G

Page 16 of 17

EXHIBIT INDEX

	Found on Sequentially
Exhibit	Numbered Page

Exhibit A: Agreement of Joint Filing	17

CUSIP NO. 00288U106

13G

Page 17 of 17

exhibit A

Agreement of Joint Filing

The Reporting Persons hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares of AbCellera Biologics Inc. shall be filed on behalf of each of the Reporting Persons. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies.

Get the next $ABCL alert in real time by email

Date	Price Target	Rating	Analyst
8/20/2024		Buy → Hold	The Benchmark Company
2/22/2024	$9.00	Hold → Buy	The Benchmark Company
12/5/2023	$6.00	Overweight	KeyBanc Capital Markets
11/6/2023		Buy → Hold	The Benchmark Company
10/13/2023	$20.00	Overweight	Piper Sandler
2/28/2023		Outperform	Cowen
12/15/2022	$30.00	Buy	Goldman
11/16/2022	$29.00	Buy	Truist

SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $ABCL

$ABCL SEC Filings

SEC Form 10-Q filed by AbCellera Biologics Inc.

AbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by AbCellera Biologics Inc.

$ABCL Press Releases

Fastest customizable press release news feed in the world

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Reports Q3 2024 Business Results

$ABCL Financials

Live finance-specific insights

$ABCL Large Ownership Changes

This live feed shows all institutional transactions in real time.

AbCellera Reports Q3 2024 Business Results

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Reports Q2 2024 Business Results

Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

SEC Form SC 13G filed by AbCellera Biologics Inc.

SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

$ABCL Market Insights

Live Market Insights

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $5

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7

AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate

$ABCL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Hansen Carl L. G. exercised 56,125 shares at a strike of $2.70, increasing direct ownership by 7% to 841,875 units (SEC Form 4)

Large owner Thermopylae Holdings Ltd. bought $739,977 worth of shares (283,516 units at $2.61), increasing direct ownership by 0.51% to 56,086,009 units (SEC Form 4)

Chief Operating Officer Lecault Veronique exercised 83,334 shares at a strike of $0.19, increasing direct ownership by 4% to 2,123,456 units (SEC Form 4)

$ABCL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AbCellera Biologics downgraded by The Benchmark Company

AbCellera Biologics upgraded by The Benchmark Company with a new price target

KeyBanc Capital Markets initiated coverage on AbCellera Biologics with a new price target

$ABCL Leadership Updates

Live Leadership Updates

AbCellera Announces Resignation of Board Member

DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

AbCellera Announces Changes to Its Board of Directors

$ABCL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Thermopylae Holdings Ltd. bought $739,977 worth of shares (283,516 units at $2.61), increasing direct ownership by 0.51% to 56,086,009 units (SEC Form 4)

Montalbano John S. bought $137,400 worth of shares (30,000 units at $4.58), increasing direct ownership by 54% to 86,000 units (SEC Form 4)

Hayden Michael R bought $98,200 worth of shares (20,000 units at $4.91) (SEC Form 4)

Recent Analyst Ratings for
$ABCL

$ABCL
SEC Filings

$ABCL
Press Releases

$ABCL
Financials

$ABCL
Large Ownership Changes

$ABCL
Market Insights

$ABCL
Insider Trading

$ABCL
Analyst Ratings

$ABCL
Leadership Updates

$ABCL
Insider Purchases